Detalhe da pesquisa
1.
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.
Haematologica
; 97(9): 1348-56, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22419581
2.
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.
Cytotherapy
; 14(9): 1131-43, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22900959
3.
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
Cytotherapy
; 13(5): 618-28, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21171821
4.
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
Br J Haematol
; 150(5): 554-64, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20618329
5.
Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy.
Clin Adv Hematol Oncol
; 8(7): 486-98, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20864917
6.
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Clin Cancer Res
; 14(9): 2775-84, 2008 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18451245
7.
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.
Br J Haematol
; 143(5): 641-53, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18950462
8.
Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.
Cancer Res
; 65(21): 10041-9, 2005 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16267030
9.
NY-ESO-1 immunotherapy for multiple myeloma.
Leuk Lymphoma
; 47(10): 2037-48, 2006 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17071474
10.
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
J Immunother
; 38(1): 24-36, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25415285
11.
Profile of elotuzumab and its potential in the treatment of multiple myeloma.
Blood Lymphat Cancer
; 2014(4): 15-27, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26005365
12.
Clinical grade purification and expansion of natural killer cells.
Crit Rev Oncog
; 19(1-2): 121-32, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24941378
13.
Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector.
Vaccine
; 32(8): 938-43, 2014 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-24406390
14.
Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels.
PLoS One
; 8(1): e54610, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23372742
15.
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
Mol Cancer Ther
; 8(9): 2616-24, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19723891
16.
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
Blood
; 111(3): 1309-17, 2008 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17947507
17.
Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
J Immunother
; 30(8): 847-54, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-18049337
18.
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.
Blood
; 105(10): 3939-44, 2005 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15671442